Teva Pharmaceutical (TEVA) Slammed Early on FY13 Warning
Tweet Send to a FriendGet Alerts TEVAQ Hot Sheet
Trade TEVAQ Now!
Teva Pharmaceutical Industries (NYSE: TEVA) is trading down 5.3 percent following lower guidance announced moments ago.
Teva Pharmaceutical said it expects FY13 adjusted EPS of $4.85 - $5.15, versus the consensus of $5.63. The company is targeting revs of $19.5 - $20.5 billion, versus the consensus of $20.82 billion.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Teva Pharmaceutical said it expects FY13 adjusted EPS of $4.85 - $5.15, versus the consensus of $5.63. The company is targeting revs of $19.5 - $20.5 billion, versus the consensus of $20.82 billion.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- NetApp (NTAP) Tops Q4 EPS by 1c; Boosts Buyback, Plans Job Cuts, Initiates Dividend
- TJX Cos. (TJX) Reports In-Line Q1 EPS; Guides Q2 EPS, Narrows FY14 Outlook
- Royalty Pharma Raises Elan (ELN) Bid to $12.50/share
Create E-mail Alert Related Categories
Guidance, Hot Guidance, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
